Haier Biomedical (SHA: 688139) captured the No. 1 position among Chinese-owned brands in global life science laboratory equipment sales and overseas sales in the same category, based on 2025 figures published by Euromonitor International and released 28 May 2026.

The Qingdao-headquartered manufacturer reached the ranking through a three-phase international expansion that has produced a compound annual growth rate above 20 percent. The dual designation covers total global revenue and overseas revenue for Chinese-owned suppliers of life science laboratory equipment, drawing on Euromonitor's market data across all regions.

What does the Euromonitor ranking actually measure?

Euromonitor International, one of the largest independent market research firms, supplies benchmarks that procurement officers and industry analysts use to compare suppliers. The two No. 1 slots apply to all global sales revenue and overseas sales revenue for Chinese-owned brands in the life science laboratory equipment segment. No comparable ranking against Western or Japanese suppliers was disclosed in the release.

For procurement teams weighing Chinese vendors against established incumbents, the independent third-party verification adds a layer of due diligence. Haier Biomedical framed the result as evidence that it is "competing at the highest level against established international manufacturers."

How did the company build a 160-country footprint?

Haier Biomedical's overseas work began with targeted engagement with UNICEF and the World Health Organization, focused on solar-powered vaccine cold-chain storage. The company then scaled distribution to 160 countries through more than 800 active dealer relationships. The current phase concentrates on regional operational depth: local warehousing, sales, marketing, product planning, and R&D.

Three overseas R&D centres now operate in the UK, Italy, and Japan, each addressing specific product lines. The UK site focuses on automation and centrifuge technology. Italy covers cold chain and automation storage. Japan handles incubators and biosafety cabinets. UK and continental European product specialists provide on-site GMP compliance, air safety, and sample purification support.

Service standards developed in the US and UK are now being replicated across the EU, Southeast Asia, and South Asia, according to the release.

What does the Q1 2026 numbers tell R&D managers about regional demand?

First-quarter 2026 revenue in Germany, Australia, and Canada grew more than 50 percent year on year. Eastern Europe, South Asia, and Brazil each exceeded 100 percent year-on-year growth. Centrifuges and incubators both doubled in unit volume.

These growth rates apply to revenue, not unit share, and Haier has not disclosed base figures for any region. R&D managers evaluating shipment reliability should request local inventory levels before committing to procurement timelines, especially as the company expands regional warehousing.

Which pharma supply chains already run on Haier equipment?

Haier Biomedical supplies multiple pharmaceutical companies in Switzerland, Germany, Denmark, Italy, Singapore, the United States, Israel, and India. The 28 May release does not name specific pharmaceutical customers or disclose contract values.

In US energy-efficiency rankings, the company's Ultra Energy series holds all eight top positions in its Energy Star category, making it the bestselling line in that segment.

What should R&D procurement teams verify before switching?

Procurement officers evaluating the vendor should examine four data points the release does not address: total installed base outside China, average service response time by region, warranty terms for the Ultra Energy series, and validation documentation for GMP-regulated workflows.

The release's strongest verifiable claim — the Euromonitor ranking — applies only to Chinese-owned brands, not the global market overall. The company also discloses no independent benchmarking against rivals such as Thermo Fisher, Eppendorf, or PHCbi.

Haier Biomedical's next test will be whether its regional R&D and warehousing build-out can sustain the 20 percent compound growth rate as Eastern European and South Asian sales scale past their current bases, and whether the 28 May 2026 figures hold up when Euromonitor publishes its 2026 update.